Commercial $1.5 Billion Cancer Drug Facility to Be Built by...

$1.5 Billion Cancer Drug Facility to Be Built by AstraZeneca in Singapore


AstraZeneca is reportedly planning to build a $1.5 billion facility in Singapore to manufacture antibody-drug conjugates (ADCs) and targeted cancer therapies. This facility will help the drugmaker establish its first end-to-end ADC production, supported by the Singapore Economic Development Board (EDB). The company has not disclosed potential financial incentives from the Singapore government.

AstraZeneca has been expanding its supply chain in countries such as China, Indonesia, and India in recent years. The company is involved in producing the breast cancer therapy Enhertu in Japan, among other countries. ADCs are engineered antibodies designed to target tumor cells and deliver toxic agents.

ADCs are produced through several steps, including antibody generation, production of a chemotherapy drug and its linker, conjugation of these elements, and filling the prepared ADC substance. AstraZeneca has numerous ADCs in its pipeline, including six wholly-owned ADCs entering clinical trials and more in preclinical development.

Png Cheong Boon, the chairperson of the EDB, welcomed AstraZeneca’s plans, stating that the launch of precision medicine research and manufacturing in Singapore would benefit the company and support Singapore’s development by generating job and economic growth opportunities.

The biopharmaceutical and medical technology industry, a crucial element of Singapore’s economy, contributed 3% to Singapore’s gross domestic product and supplied over S$39 billion worth of products to the international market in 2022, according to the EDB.

The construction of AstraZeneca’s plant, the company’s first manufacturing investment in Singapore, is expected to be completed by the end of 2024. It is anticipated to begin operations in 2029, with zero carbon emissions from the facility from Day 1, according to the company.

Latest news

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you